was read the article
array:21 [ "pii" => "X2013251409033552" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.6.5486.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:557-61" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5051 "formatos" => array:3 [ "EPUB" => 258 "HTML" => 4122 "PDF" => 671 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699509033555" "issn" => "02116995" "doi" => "10.3265/Nefrologia.2009.29.6.5486.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2009;29:557-61" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7690 "formatos" => array:3 [ "EPUB" => 252 "HTML" => 6819 "PDF" => 619 ] ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Evolución de receptores de trasplante renal de alto y bajo riesgo inmunológico sometidos a diferente inmunosupresión" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "557" "paginaFinal" => "561" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Evolution of high and low immunological risk renal transplant recipients subjected to different immunosuppressive treatments" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "448527_figura1.jpg" "Alto" => 323 "Ancho" => 600 "Tamanyo" => 120150 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Antonio Franco Esteve, E. Cotilla, S. Roca, L. Jiménez, J. Sánchez Paya, C. Sillero, J. Olivares" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Antonio" "apellidos" => "Franco Esteve" ] 1 => array:2 [ "Iniciales" => "E." "apellidos" => "Cotilla" ] 2 => array:2 [ "Iniciales" => "S." "apellidos" => "Roca" ] 3 => array:2 [ "Iniciales" => "L." "apellidos" => "Jiménez" ] 4 => array:2 [ "Iniciales" => "J." "apellidos" => "Sánchez Paya" ] 5 => array:2 [ "Iniciales" => "C." "apellidos" => "Sillero" ] 6 => array:2 [ "Iniciales" => "J." "apellidos" => "Olivares" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251409033552" "doi" => "10.3265/Nefrologia.2009.29.6.5486.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033552?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033555?idApp=UINPBA000064" "url" => "/02116995/0000002900000006/v0_201502091341/X0211699509033555/v0_201502091341/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251409033544" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.6.5511.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:562-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4575 "formatos" => array:3 [ "EPUB" => 276 "HTML" => 3712 "PDF" => 587 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Genetic analysis (PKD2) of autosomal dominant polycystic kidney disease" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "562" "paginaFinal" => "568" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Análisis genético (PKD2) de la poliquistosis renal autosómica dominante" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "44918078_f1_p564.jpg" "Alto" => 395 "Ancho" => 824 "Tamanyo" => 36029 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pilar Fraile Gómez, P. García-Cosmes, J.M. Tabernero Romo, E. Corral Moro, R. González Sarmiento" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Pilar" "apellidos" => "Fraile Gómez" ] 1 => array:2 [ "Iniciales" => "P." "apellidos" => "García-Cosmes" ] 2 => array:2 [ "Iniciales" => "J.M." "apellidos" => "Tabernero Romo" ] 3 => array:2 [ "Iniciales" => "E." "apellidos" => "Corral Moro" ] 4 => array:2 [ "Iniciales" => "R." "apellidos" => "González Sarmiento" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699509033547" "doi" => "10.3265/Nefrologia.2009.29.6.5511.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033547?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033544?idApp=UINPBA000064" "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033544/v0_201502091612/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251409033579" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.6.5490.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:548-56" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4377 "formatos" => array:3 [ "EPUB" => 259 "HTML" => 3513 "PDF" => 605 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Health related quality of life in patients with chronic kidney disease without dialysis or transplant: a random sample from two insurance companies. Medellín, Colombia, 2008" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "548" "paginaFinal" => "556" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Calidad de vida en pacientes con enfermedad renal crónica sin diálisis ni trasplante de una muestra aleatoria de dos aseguradoras en salud. Medellín, Colombia, 2008" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "44618078_t1_p551.jpg" "Alto" => 251 "Ancho" => 827 "Tamanyo" => 53521 ] ] "descripcion" => array:1 [ "en" => "Distribution of socio-demographic and clinical characteristics by age and sex in CKD patients without dialysis or transplant. Medellín, 2008" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carlos Enrique Yepes Delgado, M. Montoya Jaramillo, B.E. Orrego Orozco, M.H. Cuéllar Santaella, J.J. Yepes Núñez, J.P. López Muñoz, M.V. Salguero Bermonth, R.D. Gómez Arias" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Carlos Enrique" "apellidos" => "Yepes Delgado" ] 1 => array:2 [ "Iniciales" => "M." "apellidos" => "Montoya Jaramillo" ] 2 => array:2 [ "Iniciales" => "B.E." "apellidos" => "Orrego Orozco" ] 3 => array:2 [ "Iniciales" => "M.H." "apellidos" => "Cuéllar Santaella" ] 4 => array:2 [ "Iniciales" => "J.J." "apellidos" => "Yepes Núñez" ] 5 => array:2 [ "Iniciales" => "J.P." "apellidos" => "López Muñoz" ] 6 => array:2 [ "Iniciales" => "M.V." "apellidos" => "Salguero Bermonth" ] 7 => array:2 [ "Iniciales" => "R.D." "apellidos" => "Gómez Arias" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699509033571" "doi" => "10.3265/Nefrologia.2009.29.6.5490.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033571?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033579?idApp=UINPBA000064" "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033579/v0_201502091612/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Evolution of high and low immunological risk renal transplant recipients subjected to different immunosuppressive treatments" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "557" "paginaFinal" => "561" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Antonio Franco Esteve, E. Cotilla, S. Roca, L. Jiménez, J. Sánchez Paya, C. Sillero, J. Olivares" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Antonio" "apellidos" => "Franco Esteve" "email" => array:1 [ 0 => "franco_ant@gva.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "Iniciales" => "E." "apellidos" => "Cotilla" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:3 [ "Iniciales" => "S." "apellidos" => "Roca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 3 => array:3 [ "Iniciales" => "L." "apellidos" => "Jiménez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 4 => array:3 [ "Iniciales" => "J." "apellidos" => "Sánchez Paya" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 5 => array:3 [ "Iniciales" => "C." "apellidos" => "Sillero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 6 => array:3 [ "Iniciales" => "J." "apellidos" => "Olivares" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital General Universitario de Alicante, Alicante, Alicante, España, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evolución de receptores de trasplante renal de alto y bajo riesgo inmunológico sometidos a diferente inmunosupresión" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "44818078_t1_p559.jpg" "Alto" => 306 "Ancho" => 826 "Tamanyo" => 33468 ] ] "descripcion" => array:1 [ "en" => "General characteristics of high and low risk groups" ] ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Thymoglobulin is a polyclonal agent made up of a vast variety of specific antibodies against several lymphocyte cell surface markers: CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLADR and HLA class I.<span class="elsevierStyleSup">1</span> Treatment with polyclonal antibodies induces significant T cell depletion, with remarkable inter-individual variation,<span class="elsevierStyleSup">2</span> which makes monitoring essential to prevent either acute rejection or excessive immunosuppression.<span class="elsevierStyleSup">3,4</span></p><p class="elsevierStylePara">Due to its potency, this drug is part of the immunosuppression regime for high immunological risk renal transplant recipients,<span class="elsevierStyleSup">4,5</span> while it is not included in the immunosuppression protocol used for low risk patients.<span class="elsevierStyleSup">6,7</span> Selection criteria for high risk group are set by clinical and immunological data for patients capable of developing a significant immunological response that would trigger a high rate of acute rejection and graft loss.<span class="elsevierStyleSup">4,5,8</span></p><p class="elsevierStylePara">We have evaluated the incidence of acute rejection, opportunistic infections, and non-dermatological malignancies, as well as graft and recipient survival, among a group of high immunological risk recipients with induction treatment that included thymoglobulin against a low risk group. Both group patients received grafts from the same donors.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">MATERIAL AND METHODS</span></p><p class="elsevierStylePara">This is a prospective and observational study over recipients to renal graft transplanted in our hospital during the period between 2002 and 2006.</p><p class="elsevierStylePara">All grafts were from dead donors for 50 high immunological risk patients who were transplanted with their 50 low immunological risk counterpart patients.</p><p class="elsevierStylePara">The high risk group included patients with high rate of antibodies (> 50% antibodies against panel), recipients who had lost their first graft due to early rejection, cross match positive, black race, or HLA incompatibility according to immunology service centre criterion. Immunosuppression consisted in administering thymoglobulin to maintain T cell count at 10/μl, tacrolimus (FK506) after 5 days to reach serum concentration of 12-15ng/ml, mycophenolate mofetil (MMF) at 1,000mg/24 h and steroids (1mg/kg/24 h) in decreasing dosage. All recipients received ganciclovir prophylaxis for CMV for as long as they were given thymoglobulin. Ganciclovir dose was 1-1.25mg/kg and the mean by recipient was 5.5 dose/patient.</p><p class="elsevierStylePara">The low risk group included patients without the characteristics mentioned above; they were immunosuppressed with cyclosporine A (CYA), MMF and steroids (1mg/kg/24 h) in decreasing dosage. CYA dosing was set to reach 1,700ng/ml 2 hours after dose. MMF dosing was 2,000mg/24 h; it was reduced when intolerance or leukopenia appeared. All CMV seronegative recipients who received seropositive grafts received ganciclovir prophylaxis for 100 days. CMV infection was diagnosed when the patient developed clinical data of infection in presence of antigenaemia > 10 cells/2,000,000 leukocytes.</p><p class="elsevierStylePara">Acute rejection events were diagnosed following a histological study, and the affected patients received 500mg methylprednisolone IV daily during 3 days. When patient presented with resistance to the above treatment or acute rejection, Banff stage IIB or III, thymoglobulin was administered with the same monitoring pattern as in the prophylactic treatment.<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">Recipients that lost their graft due to technical failure during immediate postoperative stage were excluded together with their counterparts. Minimum follow-up for all recipients was one year after transplant, with a mean of 41.7 months (percentile 25: 22.7; percentile 75: 57.2).</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical study</span></p><p class="elsevierStylePara">Description of patient baseline characteristics was performed through percentage for qualitative variables, and, for quantitative variables with normal distribution, mean standard deviation was used; while for those not following normal distribution mean percentiles were used. Chi square test was performed for qualitative variables, whereas for qualitative variables with parametric distribution Student¿s t-test was used. P < 0.05 was considered statistically significant.</p><p class="elsevierStylePara">Kaplan-Meier method was used to estimate survival function of survival times in both groups.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">Both groups were similar with respect to gender and age, as they shared the same donors, recipient age and HLA incompatibilities, but the percentage of male recipients was significantly higher in the low risk group. The percentage of re-transplants and recipients with high rate of antibodies was significantly higher in the high risk group, according to the selection criteria of the study (table 1).</p><p class="elsevierStylePara">Regarding incidence by CMV infection and nondermatological malignancies during follow-up, no significant differences were observed (table 2).</p><p class="elsevierStylePara">The low risk group presented with two neoplasias, one acute leukaemia, with CYA, MMF, and steroids with no added risk factor; this required chemotherapy and immunosuppression switch to m-TOR (sirolimus) with good evolution; they also presented with a posttransplant lymphoproliferative disorder which evolved favourably but with graft loss when immunosuppressant was minimized and rituximab was administered. No episodes were observed in the high risk group (table 2).</p><p class="elsevierStylePara">The incidence of acute rejection was significantly higher (p < 0.03) in the low risk group (table 2) and 30% against 6% in the high risk group. There were episodes of acute rejection resistant to corticoids in the low risk group that were resolved with thymoglobulin in the three recipients.</p><p class="elsevierStylePara">Recipient survival was 97.9% at 12 and 36 months in both groups, and the graft survival was 89.8% and 84.8% in the high risk group against 93.8% and 90.4% in the low risk group at 12 and 36 months (figure 1), with no significant differences observed.</p><p class="elsevierStylePara">Three patients died in the high risk group: two with functioning graft at 12 and 53 months, and the third at 42 months after chronically having lost his graft at month 4. Other 5 recipients lost their grafts, one of them due to acute rejection and the other at 4, 5, 17 and 24 months chronically; one of them due to non-compliance with treatment.</p><p class="elsevierStylePara">Two patients died in the low risk group, at 2 and 37 months due to abdominal sepsis and vascular pathology with functioning graft, respectively. Other 2 recipients lost their grafts chronically at 9 and 2 months, the last one when immunosuppression was minimised to treat diffuse lymphoproliferative disorder.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"></span>Inclusion criteria into the high immunological risk group were identical to those used in other studies and to those applied in clinical practice<span class="elsevierStyleSup">4,5,8 </span>and permit identifying a group of patients with a theoretically high immunologic response. Some authors include delayed graft function when assessing a score to include recipient as high risk,<span class="elsevierStyleSup">4</span> however that is not our case.</p><p class="elsevierStylePara">In this series acute rejection rate was 6% in the group receiving thymoglobulin, a result that overlapped with other series published with the same characteristics regarding donor-recipient,<span class="elsevierStyleSup">10</span> but it was high in the low risk group recipients when compared against other series published with the same immunosuppression pattern.<span class="elsevierStyleSup">11</span> We must insist at this point in the fact that all acute rejections were diagnosed histologically, and no explanation has been found for disagreement regarding this information. This high rate of acute rejection, together with its lower incidence gathered in the literature with an immunosuppression pattern based on FK against cyclosporine,<span class="elsevierStyleSup">6,7</span> led us to change our immunosuppression protocol in patients with low immunological risk.</p><p class="elsevierStylePara">CMV infection incidence was similar in both groups. This fact can be explained by the use of universal ganciclovir prophylaxis in the high risk group and also due to the higher incidence of acute rejection in the low risk group, which was undoubtedly what conditioned an increase in immunosuppression for that group; all this confirms published data in that acute rejection is a risk factor for the development of infection by CMV.<span class="elsevierStyleSup">12</span> Valganciclovir prophylaxis in seronegative recipients who received seropositive grafts led to lower incidence of infection in this type of patients, which has already been described by other authors.<span class="elsevierStyleSup">13</span></p><p class="elsevierStylePara">Incidence of non-dermatological malignancies in both groups was low, with no incidence in the high risk group, which would be attributable to the number of patients in the series and to the fact that their follow-up was only for a medium term. It is striking that the only case of lymphoproliferative disorder after transplant occurred in the low immunological risk group, when it was to be expected amongst high risk patients, as these received thymoglobulin, which is considered a high risk drug fostering development of this disorder.<span class="elsevierStyleSup">14</span> In our experience the incidence of lymphoproliferative disorder is 1.3%,<span class="elsevierStyleSup">15</span> similar to that described in the literature,<span class="elsevierStyleSup">16</span> and no relation has been found in our series between this incidence and the administration of monoclonal or polyclonal antibodies.<span class="elsevierStyleSup">15</span> The therapeutic strategy to deal with posttransplant lymphoproliferative disorder consists in administering rituximab and changing immunosuppression to m-TOR, which is well documented in the literature,<span class="elsevierStyleSup">17</span> but which was not efficient with our patient.</p><p class="elsevierStylePara">Both patient and graft survival was similarly high in both groups; although it should be considered that early losses were excluded from the study. All leads to believe that the use of a potent immunosuppressant was decisive in following up graft survival in high risk group, and it is worth noting that it did not entail an increase in mortality of those recipients. Monitoring closely thymoglobulin doses by T-cell counts could have been an important factor, in low incidence of acute rejection as in the absence of side effects over immunosuppression. According to our experience, the evolution of high risk renal transplant recipients is similar to low risk patients if potent enough immunosuppression is used, which leads to significantly lower acute rejection incidence in the high risk group.<br></br></p><p class="elsevierStylePara"><a href="grande/44818078_t1_p559.jpg" class="elsevierStyleCrossRefs"><img src="44818078_t1_p559.jpg" alt="General characteristics of high and low risk groups"></img></a></p><p class="elsevierStylePara">Table 1. General characteristics of high and low risk groups</p><p class="elsevierStylePara"><a href="grande/44818078_t2_p560.jpg" class="elsevierStyleCrossRefs"><img src="44818078_t2_p560.jpg" alt="Incidence of episodes studied in high and low immunological risk groups"></img></a></p><p class="elsevierStylePara">Table 2. Incidence of episodes studied in high and low immunological risk groups</p><p class="elsevierStylePara"><a href="grande/44818078_f1_p560.jpg" class="elsevierStyleCrossRefs"><img src="44818078_f1_p560.jpg"></img></a></p><p class="elsevierStylePara">Figure 1. </p>" "pdfFichero" => "P-E-S-A448-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:4 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec438091" "palabras" => array:1 [ 0 => "Timoglobulina" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec438093" "palabras" => array:1 [ 0 => "Rechazo agudo" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec438095" "palabras" => array:1 [ 0 => "Riesgo inmunológico" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec438097" "palabras" => array:1 [ 0 => "Trasplante renal" ] ] ] "en" => array:4 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec438092" "palabras" => array:1 [ 0 => "Thymoglobulin" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec438094" "palabras" => array:1 [ 0 => "Acute rejection" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec438096" "palabras" => array:1 [ 0 => "Immunological risk" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec438098" "palabras" => array:1 [ 0 => "Renal transplantation" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:1 [ "resumen" => "We evaluate the incidence of acute rejection, oportunistic infections and non-dermatological malignancies, graft and recipient survival between a group of high immunological risk renal transplant recipients and a group of patients without immunological risk, who received grafts from the same cadaveric donors since 2001 to 2006. This is a prospective and observational study. The risk group (n = 50) included patients with high rate of antibodies (>50%), recipients who had lost their first graft due to early rejection, cross match positive, black race or important histoincompatibility. They received thymoglobulin to mantain T-cell around 10 cells/μl, FK 506 after five days, mycophenolate mofetyl and steroids, with ganciclovir prophylaxis for CMV. The normal risk group (n = 50), cyclosporine, mycophenolate mofetil and steroids. Recipients who lost their graft due to technical failure were excluded. All CMV seronegative recipients who received seropositive grafts were treated with valganciclovir for 100 days. The mean follow-up was 42.7 months. Both groups were similar respect to donor and recipient gender and age, HLA incompatibility, but the percentage of patients with high rate of performed antibodies and second transplant recipients was higher in the high risk group according to the criteria of the study The incidence of acute rejection histologically diagnosed was higher in the normal risk group (30% against 6 %, p = 0.03). There was no difference in opportunistic infections or malignancies, although 2 recipients of the normal risk group developed lymphoproliferative disorders. The recipients survival was 97.9% at 1 and 3 years in both groups, and the graft survival was 89.8% and 84.8% in the high risk group against 93.8% and 90.4% at 1 and 3 years in the normal group (p = NS). We conclude that the evolution of high risk renal transplant recipients is similar to normal risk patients if a potent enough immunosuppression is used. The incidence of acute rejection was higher in the normal risk group" ] "es" => array:1 [ "resumen" => "<p class="elsevierStylePara">La timoglobulina forma parte del esquema de inmunosupresión en receptores de trasplante renal de alto riesgo inmunológico. Hemos comparado, en un estudio observacional y prospectivo, la incidencia de rechazo agudo, de infecciones oportunistas y de neoplasias, así como la supervivencia del injerto y del receptor, entre un grupo de 50 receptores de alto riesgo inmunológico con tratamiento de inducción que incluía timoglobulina, frente a un grupo de bajo riesgo cuyos 50 receptores recibieron injertos procedentes de los mismos donantes, en nuestro hospital en el período 2002-2006. El grupo de alto riesgo estaba formado por receptores hiperinmunizados (>50%), retrasplantes con pérdida de injerto previa inmunológica, reactividad en prueba cruzada, raza negra, o alta incompatiblidad HLA. La inmunosupresión consistió en administrar timoglobulina a dosis que mantuvieran un recuento de linfocitos T inferior a 10 μl, FK a partir del día 5, micofenolato mofetil y esteroides, y los pacientes recibían profilaxis frente al CMV con ganciclovir. El grupo de bajo riesgo incluía los pacientes sin estas características, a quienes se les realizaba la inmunosupresión con ciclosporina A, micofenolato mofetil y prednisona. Todos los receptores seronegativos con donantes seropositivos recibieron valganciclovir durante 100 días. Se descartaron aquellos pacientes en quienes se perdió el injerto por causas técnicas en el postoperatorio inmediato, junto con sus parejas. En todos los receptores se llevó a cabo un seguimiento mínimo de un año posterior al trasplante, con una mediana de 41,7 meses. Los dos grupos eran homogéneos en cuanto a edad y sexo del donante, edad del receptor e incompatibilidades HLA, pero el porcentaje de receptores varones era significativamente superior en el grupo control. El porcentaje de retrasplantes y de receptores hiperinmunizados fue significativamente superior en el grupo de alto riesgo, de acuerdo con los criterios de selección del grupo. La incidencia de rechazo agudo histológicamente probado fue superior en el grupo control (el 30 frente al 6%; p =0,003) y no se han producido diferencias significativas en cuanto a la incidencia de infecciones oportunistas ni de neoplasias; se ha diagnosticado un caso de leucemia aguda y un caso de enfermedad linfoproliferativa en el grupo de bajo riesgo. La supervivencia de los pacientes fue del 97,9% en ambos grupos al año y a los 3 años, mientras que la supervivencia del injerto fue del 89,8 y del 84,8% en el grupo de alto riesgo frente al 93,8 y al 90,4% en el grupo sin riesgo al año y a los 3 años (p = NS). En nuestra experiencia, la evolución de receptores de trasplante renal con alto riesgo inmunológico es similar a la del grupo de riesgo normal mientras se utilice una inmunosupresión lo suficientemente potente, que condicionó una incidencia de rechazo agudo significativamente menor en el grupo de alto riesgo.</p>" ] ] "multimedia" => array:3 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "44818078_t1_p559.jpg" "Alto" => 306 "Ancho" => 826 "Tamanyo" => 33468 ] ] "descripcion" => array:1 [ "en" => "General characteristics of high and low risk groups" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "44818078_t2_p560.jpg" "Alto" => 116 "Ancho" => 827 "Tamanyo" => 17448 ] ] "descripcion" => array:1 [ "en" => "Incidence of episodes studied in high and low immunological risk groups" ] ] 2 => array:7 [ "identificador" => "fig3" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "44818078_f1_p560.jpg" "Alto" => 436 "Ancho" => 824 "Tamanyo" => 58243 ] ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:17 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, et al. Polyclonal rabbit anti thymocyte globuline triggers b-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79:1507-15. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15940039" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Butcher M, Thibault A, Al Naijar JF, Valentin A, Gueraou A, Nivet H, et al. Monitoring of ATG theraphy by flow cytometry and lymphocyte counts in renal transplantation. Transplant Proc 1996;28:2817-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8908076" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pedi VR, Bryant M, Chaudhury PR, Woodle ES, First MR. Safety, efficacy and cost-analysis of thymoglobulin induction therapy with intermittent dosing based on CD3 lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002;73:1514-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12023634" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Brenan DC, Dalter JA, Lake KD, Cibrik D, Del Castillo D. Thymoglobulin induction study group. Rabbit antithymocyte globulin versus baxiliximab in renal transplantation. N Engl J Med 2006;355:1967-77. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17093248" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Thibaudin D, Alamartine E, Filippis JP, Diab N, Lavet B, Bertoux F. Advantage of antithymocyte globuline induction in sensitized kidneys recipients: A randomized prospective study comparing induction with and with out antithymocyte globuline. Nephrol Dial Transplant 1998;13:711-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9550651" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pirsch JD, Miller J, Deierhoi MH, Vicenti F, Filo RS, for the FK 506 Kidney Transplant Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63:977-83." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Margreiter R, for the European Tacrolimus versus Ciclosporine Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporine microemulsion in renal transplantation. A randomised multicentre study. Lancet 2002;359:741-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11888584" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sancho A, Gavela J, Crespo JF, Górriz JL, Ávila A, Núñez A, et al. Trasplante renal en presencia de una prueba cruzada positiva. Nefrología 2006;26:261-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16808265" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Franco A, Álvarez L, Gimeno A, Sen ML, Muñoz C, Sánchez-Paya J, et al. Study of the correlation between two methods used to monitor thymoglobulin therapy in renal transplantation. Transplant Proc 2003;35:1778-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12962792" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Gurk-Turner C, Airee R, Phylosophe B, Kukuruga D, Drachenberg C, Harrian A. Thymoglobulin dose optimization for induction therapy in high risk transplant recipients. Transplantation 2008;85:1425-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18497682" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Mathew TH. A blinded long term randomited multicenter study of Mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998;65:1450-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9645801" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cope AV, Sabin C, Burroughs A, Rolles K, Griffths PD, Emery VC. Interrelations among cuantity of human Cytomegalovirus ADN in blood, donor recipient serostatus and administration of Methylprednisolone at risk factors for CMV disease following liver transplantation. J Infect Dis 1997;176:1484-90. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9395358" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Girado L, Nabella N, Díaz JM, Fáculo C, Maderuelo A, Margall N, et al. Tratamiento profiláctico y anticipado de la infección por Citomegalovirus en pacientes trasplantados renales mediante Valganciclovir oral. Nefrología 2008;28:293-300. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18590496" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Opelz G, Dohler B. Lymphomas after solid organ transplantation. A collaborative transplant study report. Am J Transplant 2003;4:222-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14974943" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Franco A, Jiménez L, Aranda I, Álvarez L, González M, Rocamora N, et al. La enfermedad linfoproliferativa difusa postrasplante renal y su relación con el virus Epstein-Barr. Experiencia de un Centro. Nefrología 2002;22:463-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12497748" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Opelz G, Henderson R. Incidence of non Hodgkin lymphoma in kidney and heart transplant recipiens. Lancet 1993;342:1514-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7902900" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "García VD, Bonamigo Filho JL, Neuman J, Fogliatto L, Geiger AM, García CD, et al. Rituximab in association with Rapamycine for posttransplant lymphoproliferative disease treatment. Transplant Int 2003;16:202-6." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033552/v0_201502091612/en/main.assets" "Apartado" => array:4 [ "identificador" => "35441" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002900000006/v0_201502091611/X2013251409033552/v0_201502091612/en/P-E-S-A448-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033552?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 10 | 9 | 19 |
2024 October | 66 | 42 | 108 |
2024 September | 56 | 27 | 83 |
2024 August | 75 | 55 | 130 |
2024 July | 61 | 32 | 93 |
2024 June | 86 | 33 | 119 |
2024 May | 86 | 34 | 120 |
2024 April | 82 | 22 | 104 |
2024 March | 60 | 28 | 88 |
2024 February | 58 | 40 | 98 |
2024 January | 50 | 33 | 83 |
2023 December | 56 | 23 | 79 |
2023 November | 65 | 24 | 89 |
2023 October | 81 | 35 | 116 |
2023 September | 88 | 30 | 118 |
2023 August | 97 | 42 | 139 |
2023 July | 65 | 57 | 122 |
2023 June | 51 | 30 | 81 |
2023 May | 81 | 54 | 135 |
2023 April | 48 | 24 | 72 |
2023 March | 47 | 35 | 82 |
2023 February | 48 | 20 | 68 |
2023 January | 52 | 24 | 76 |
2022 December | 59 | 38 | 97 |
2022 November | 55 | 39 | 94 |
2022 October | 50 | 41 | 91 |
2022 September | 62 | 28 | 90 |
2022 August | 69 | 56 | 125 |
2022 July | 73 | 44 | 117 |
2022 June | 76 | 49 | 125 |
2022 May | 93 | 45 | 138 |
2022 April | 113 | 48 | 161 |
2022 March | 84 | 45 | 129 |
2022 February | 75 | 47 | 122 |
2022 January | 121 | 36 | 157 |
2021 December | 84 | 47 | 131 |
2021 November | 87 | 40 | 127 |
2021 October | 52 | 47 | 99 |
2021 September | 53 | 34 | 87 |
2021 August | 72 | 41 | 113 |
2021 July | 74 | 38 | 112 |
2021 June | 55 | 32 | 87 |
2021 May | 51 | 32 | 83 |
2021 April | 123 | 34 | 157 |
2021 March | 68 | 33 | 101 |
2021 February | 69 | 19 | 88 |
2021 January | 62 | 18 | 80 |
2020 December | 156 | 14 | 170 |
2020 November | 46 | 12 | 58 |
2020 October | 38 | 23 | 61 |
2020 September | 46 | 3 | 49 |
2020 August | 46 | 16 | 62 |
2020 July | 62 | 8 | 70 |
2020 June | 53 | 16 | 69 |
2020 May | 49 | 9 | 58 |
2020 April | 56 | 13 | 69 |
2020 March | 47 | 5 | 52 |
2020 February | 67 | 21 | 88 |
2020 January | 67 | 15 | 82 |
2019 December | 57 | 35 | 92 |
2019 November | 62 | 20 | 82 |
2019 October | 72 | 19 | 91 |
2019 September | 71 | 31 | 102 |
2019 August | 49 | 24 | 73 |
2019 July | 78 | 24 | 102 |
2019 June | 70 | 15 | 85 |
2019 May | 56 | 22 | 78 |
2019 April | 95 | 48 | 143 |
2019 March | 57 | 25 | 82 |
2019 February | 34 | 21 | 55 |
2019 January | 36 | 20 | 56 |
2018 December | 71 | 32 | 103 |
2018 November | 54 | 15 | 69 |
2018 October | 72 | 10 | 82 |
2018 September | 71 | 18 | 89 |
2018 August | 43 | 16 | 59 |
2018 July | 43 | 14 | 57 |
2018 June | 43 | 14 | 57 |
2018 May | 46 | 12 | 58 |
2018 April | 48 | 3 | 51 |
2018 March | 35 | 7 | 42 |
2018 February | 71 | 5 | 76 |
2018 January | 42 | 4 | 46 |
2017 December | 58 | 15 | 73 |
2017 November | 43 | 4 | 47 |
2017 October | 47 | 9 | 56 |
2017 September | 43 | 12 | 55 |
2017 August | 54 | 35 | 89 |
2017 July | 47 | 15 | 62 |
2017 June | 52 | 13 | 65 |
2017 May | 62 | 15 | 77 |
2017 April | 44 | 6 | 50 |
2017 March | 37 | 5 | 42 |
2017 February | 36 | 8 | 44 |
2017 January | 44 | 11 | 55 |
2016 December | 61 | 10 | 71 |
2016 November | 89 | 8 | 97 |
2016 October | 106 | 11 | 117 |
2016 September | 146 | 7 | 153 |
2016 August | 204 | 7 | 211 |
2016 July | 177 | 5 | 182 |
2016 June | 111 | 0 | 111 |
2016 May | 129 | 0 | 129 |
2016 April | 106 | 0 | 106 |
2016 March | 102 | 0 | 102 |
2016 February | 117 | 0 | 117 |
2016 January | 116 | 0 | 116 |
2015 December | 115 | 0 | 115 |
2015 November | 96 | 0 | 96 |
2015 October | 88 | 0 | 88 |
2015 September | 76 | 0 | 76 |
2015 August | 70 | 0 | 70 |
2015 July | 58 | 0 | 58 |
2015 June | 43 | 0 | 43 |
2015 May | 60 | 0 | 60 |
2015 April | 6 | 0 | 6 |